Anatibant

Anatibant is a potent, non-peptide antagonist of the bradykinin B2 receptor. It has demonstrated efficacy in preclinical models, reducing intracranial pressure and histopathological damage following traumatic brain injury. This makes it a valuable research tool for studying neuroinflammation and secondary injury mechanisms in both in vitro and in vivo settings.